Click here to learn more about

THE ONLY IG WITH TWO NEUROMUSCULAR INDICATIONS

US-GGL-0670v1.0 07/24

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as a replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older, as maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN). Click here to learn more about an additional neuromuscular indication.

When starting a patient on treatment with GAMMAGARD LIQUID, the correct dose and rate of administration is based on the treatment indication and the individual patient’s weight.1

Intravenous immune globulin (IVIG) administration is available for patients with primary immunodeficiency (PI), multifocal motor neuropathy (MMN). Additionally, a subcutaneous IG (SCIG) option is also available for patients with PI.1

Medicine bottle icon.See PI dosing calculator

Dose and infusion rates for PI1

Dose and infusion rates for PI1

IV Administration SC Administration
Dose 300 to 600 mg/kg every 3 to 4 weeks based on clinical response Initial dose is 1.37 x previous IV dose divided by number of weeks between IV doses

Maintenance dose is based on clinical response and target IgG trough level

Initial Rate of Infusion 0.5 mL/kg/hr (0.8 mg/kg min) for 30 minutes 40 kg BW and greater: 30 mL/site at 20 mL/hr/site

Under 40 kg BW: 20 mL/site at 15 mL/hr/site

Maintenance Infusion Rate Increase every 30 minutes (if tolerated) up to 5 mL/kg/hr (8 mg/kg/min) 40 kg BW and greater: 30 mL/site at 20 to 30 mL/hr/site

Under 40 kg BW: 20 mL/site at 15 to 20 mL/hr/site

IV Administration
Dose 300 to 600 mg/kg every 3 to 4 weeks based on clinical response
Initial Rate
of Infusion
0.5 mL/kg/hr (0.8 mg/kg min) for 30 minutes
Maintenance
Infusion Rate
Increase every 30 minutes(if tolerated) up to 5 mL/kg/hr(8 mg/kg/min)
SC Administration
Dose Initial dose is 1.37 X previous intravenous dose

Maintenance dose is based on clinical response and target IgG trough level

Initial Rate
of Infusion
40 kg BW and greater: 30 mL/site at 20 mL/hr/site

Under 40 kg BW: 20 mL/site at 15 mL/hr/site

Maintenance
Infusion Rate
40 kg BW and greater: 30 mL/site at 20 to 30 mL/hr/site

Under 40 kg BW: 20 mL/site at 15 to 20 mL/hr/site

BW = body weight.
Adjust dose according to IgG levels and clinical response, as the frequency and dose of IG may vary from patient to patient.

See MMN dosing calculator

Dose and infusion rates for MMN1

Dose and infusion rates for MMN1

IV Administration
Dose Dose range 0.5 to 2.4 grams/kg/month based on clinical response
Initial Rate of Infusion 0.5 mL/kg/hr (0.8 mg/kg/min)
Maintenance Infusion Rate Infusion rate may be increased if tolerated up to 5.4 mL/kg/hr (9 mg/kg/min)
GAMMAGARD LIQUID vial and box.

IVIG dosing for PI1

Increase every 30 minutes (if tolerated) up to 5 mL/kg/hr (8 mg/kg/min)

  • Initial infusion rate is 0.5 mL/kg/hr for 30 minutes
  • It is important to individualize rates for each patient based on clinical response and tolerability
  • Patients beginning treatment or switching from one IVIG product to another should be started at the lower infusion rates, and rates should be gradually increased as tolerated

IVIG dosing for MMN1

The dose of GAMMAGARD LIQUID may need to be adjusted to achieve the desired clinical response. In the clinical study for MMN treatment, the dose ranged from 0.5 to 2.4 g/kg/mo.

While receiving GAMMAGARD LIQUID, 9% of patients in the clinical study experienced neurological decompensation that required an increase in dose. Accordingly, dose adjustment may be necessary in order to avoid worsening of muscle weakness in patients with MMN.

Dosing calculator

Dosing range

Calculated infusion rates

300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 or 4 weeks based on clinical response

500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response

Dosing range

300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 or 4 weeks based on clinical response

Min(g) 15
Max(g) 30

Calculated infusion rates

300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 or 4 weeks based on clinical response

Time 0 hr -
0.5 hr
0.5 hr -
1 hr
1 hr -
1.5 hrs
1.5 hrs -
2 hrs
2 hrs -
2.5 hrs
2.5 hrs - end
of infusion
mL/hr 25 50 100 150 200 250

Dosing range

500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response

Min(g) 25
Max(g) 120

Calculated infusion rates

500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response

Time 0 hr -
0.5 hr
0.5 hr -
1 hr
1 hr -
1.5 hr
1.5 hr -
2 hrs
2 hrs -
2.5 hrs
2.5 hrs -
3 hrs
3 hrs - end
of infusion
mL/hr 25 50 100 150 200 250 270
GAMMAGARD LIQUID IV infusion rate table

*Weights have been rounded to the nearest pound; calculations based on this have also been rounded.

GAMMAGARD LIQUID IV maintenance infusion rate may be increased every 30 minutes based on patient tolerability.

SCIG dosing for PI

Prior to switching patients from GAMMAGARD LIQUID IVIG to SCIG, obtain the serum IgG trough level to guide subsequent dosing. To calculate the target trough IG level for SCIG treatment, add 281 mg/dL to the IG trough level obtained after the last IV treatment. Start the initial SCIG dose approximately 1 week after the last IVIG infusion.1

To guide dose adjustment, calculate the difference between the patient’s target serum IgG trough level and the actual IgG trough level during SCIG treatment1:

Change in weekly dose of GAMMAGARD LIQUID for intended IgG trough level adjustment1a

Difference between measured and target IgG trough levels

Body Weight 100 mg/dL 200 mg/dL 300 mg/dL 400 mg/dL
10 kg 2 mL 4 mL 6 mL 8 mL
20 kg 4 mL 8 mL 11 mL 15 mL
30 kg 6 mL 11 mL 17 mL 23 mL
40 kg 8 mL 15 mL 23 mL 30 mL
50 kg 9 mL 19 mL 28 mL 38 mL
60 kg 11 mL 23 mL 34 mL 45 mL
70 kg 13 mL 26 mL 40 mL 53 mL
80 kg 15 mL 30 mL 45 mL 60 mL
90 kg 17 mL 34 mL 51 mL 68 mL
100 kg 19 mL 38 mL 57 mL 75 mL
110 kg 21 mL 42 mL 62 mL 83 mL
120 kg 23 mL 45 mL 68 mL 91 mL
130 kg 25 mL 49 mL 74 mL 98 mL
140 kg 26 mL 53 mL 79 mL 106 mL

aDerived using a linear approximation to the nomogram method with a slope of 5.3 kg/dL.

Additional considerations

Ensure patients with preexisting renal insufficiency are not volume depleted; discontinue GAMMAGARD LIQUID if renal function deteriorates.1

For patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable.1

Continue reviewing safety information

There are known patient risk factors to consider with IVIG products, including GAMMAGARD LIQUID. Review important safety information, including contraindications and specific warnings and precautions to take when prescribing and monitoring patients treated with GAMMAGARD LIQUID.

IVIG bag icon.

For patients with PI, GAMMAGARD LIQUID IV is given by a healthcare professional. It can be administered at1:

  • A patient’s home
  • A physician’s office
  • A hospital
  • An infusion center

SC administration may be given by the patient or a caregiver, after they’ve been properly trained by a healthcare professional.

Looking for MMN dosing information?

Additional considerations

Ensure patients with preexisting renal insufficiency are not volume depleted; discontinue GAMMAGARD LIQUID if renal function deteriorates.1

For patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable.1

Continue reviewing safety information

There are known patient risk factors to consider with IVIG products, including GAMMAGARD LIQUID. Review important safety information, including contraindications and specific warnings and precautions to take when prescribing and monitoring patients treated with GAMMAGARD LIQUID.

For patients with MMN, GAMMAGARD LIQUID IV is given by a healthcare professional. It can be administered at:1:

  • A patient’s home
  • A physician’s office
  • A hospital
  • An infusion center

Looking for PI dosing information?

GAMMAGARD LIQUID vials.
Primary immunodeficiency icon.

Review details for GAMMAGARD LIQUID specific to PI

PI information
Multifocal motor neuropathy icon.

Review details for GAMMAGARD LIQUID specific to MMN

MMN information